Sarepta Therapeutics Inc SRPT 1.26% shares nearly doubled in September after the FDA granted accelerated approval for the company’s first drug, EXONDYS 51. However, Credit Suisse analyst Alethia Young believes Sarepta is just getting started.

Credit Suisse is anticipating the first EXONDYS 51 sales in Q4 of 2016 and sees a number of things to like about the drug and the stock. Young is confident that EXONDYS 51 will gain European approval in the near future, and Credit Suisse is predicting Sarepta could start seeing early success with its Exon 53 program next year.

Young estimates Sarepta’s drugs could eventually treat 80 percent of Duchenne Muscular Dystrophy (DMD) patients.

Credit Suisse projects roughly $400 million in annual sales for EXONDYS 51 by 2020, but the firm also sees value elsewhere.

“We estimate unadjusted peak sales for Exon 53 and 45 indications of ~$670 million and ~$700 million respectively and assume a 15 percent probability of success to each exon target,” Young explained.

Credit Suisse has initiated…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!